Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPis) have been approved for the treatment of recurrent epithelial ovarian cancer (EOC), regardless of BRCA status or homologous recombination repair deficiency. However, the low response of platinum-resistant EOC, the emergence of resistance in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xi, Wang, Liqiong, Chen, Shu, Huang, Peng, Ma, Lan, Ding, Hui, Basappa, Basappa, Zhu, Tao, Lobie, Peter E., Pandey, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250505/
https://www.ncbi.nlm.nih.gov/pubmed/35791346
http://dx.doi.org/10.1038/s43856-022-00142-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250505/
https://www.ncbi.nlm.nih.gov/pubmed/35791346
http://dx.doi.org/10.1038/s43856-022-00142-3

Ejemplares similares